Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.

Lu D, Li N, Yuan Z, Gao Y

Clinical obesity1 Oct 2026

PMID42733128PMCIDPMC13572569DOI10.1111/cob.70112PepBankPUB-42733128

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity, the GLP-1/GIP dual agonist subgroup (tirzepatide) yielded superior weight-lowering effects in subgroup analyses.
In plain wordsIn adults with obesity, the tirzepatide subgroup showed better weight loss than the other drug groups in this analysis.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction in the GLP-1/GIP dual agonist (tirzepatide) subgroup
Study
n: not reported in source
Comparator
GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analyses revealed that GLP-1/GIP dual agonists (tirzepatide) and longer treatment duration (≥ 72 weeks) yielded superior weight-lowering effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines.
Report a problemFND-4273312802

Studies that did not test the peptide alone4

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with obesity, pooled GLP-1 receptor agonists and dual agonists achieved a weighted mean weight reduction of 9.36%.
In plain wordsIn adults with obesity, the group of GLP-1 and dual-agonist drugs together gave an average weight loss of 9.36%, with large differences between studies.
Peptide
Tirzepatide
Outcome
DecreasePooled weight reduction with GLP-1RAs and dual agonists
Study
n = 40,408
Outcome group
Body weight · Metabolic and weight
Measurements
Weighted mean weight reduction
9.36%
pooled GLP-1RAs and dual agonists
Source sentences
Summary
Pooled analysis showed that GLP-1RAs and dual agonists achieved a weighted mean weight reduction of 9.36% (95% CI 7.92%-10.80%), with high interstudy heterogeneity (I² = 99.6%, p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4273312801
03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with obesity, pooled GLP-1 receptor agonists and dual agonists given for 72 weeks or longer yielded superior weight-lowering effects.
In plain wordsIn adults with obesity, GLP-1 and dual-agonist drugs together gave more weight loss when given for 72 weeks or longer.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction with treatment of 72 weeks or longer
Study
n: not reported in source
Comparator
Shorter treatment duration
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Subgroup analyses revealed that GLP-1/GIP dual agonists (tirzepatide) and longer treatment duration (≥ 72 weeks) yielded superior weight-lowering effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4273312803
04HumanNot a test of Tirzepatide aloneSystematic reviewOther
In adults with obesity, baseline anxiety or depression was positively associated with weight loss efficacy of pooled GLP-1 receptor agonists and dual agonists in meta-regression.
In plain wordsIn adults with obesity, anxiety or depression at the start was linked to more weight loss with GLP-1 and dual-agonist drugs together.
Peptide
Tirzepatide
Outcome
Not applicableBaseline anxiety or depression and weight loss efficacy
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Meta-regression beta
2.44
baseline anxiety/depression
Source sentences
Summary
Meta-regression demonstrated that baseline anxiety/depression was positively associated with weight loss efficacy (β = 2.44, p 2 = 81.34%).
1 context sentence(design, population, supporting numbers)
Summary · context
We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4273312804
05HumanNot a test of Tirzepatide aloneSystematic reviewOther
In adults with obesity, comorbid type 2 diabetes, obstructive sleep apnea and MAFLD were negatively correlated with the weight loss response to pooled GLP-1 receptor agonists and dual agonists.
In plain wordsIn adults with obesity, having type 2 diabetes, sleep apnea or fatty liver was linked to less weight loss with GLP-1 and dual-agonist drugs together.
Peptide
Tirzepatide
Outcome
Not applicableComorbid T2DM, OSA and MAFLD and weight loss response
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Comorbid Type 2 diabetes mellitus (T2DM), obstructive sleep apnea (OSA) and metabolic dysfunction-associated fatty liver disease (MAFLD) were negatively correlated with treatment response (all p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4273312805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.